Search Result

Results for "

Aβ

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (65) 5-HT Receptor (2) Acyltransferase (1) Adrenergic Receptor (1) Amino Acid Derivatives (1) Apoptosis (3) Autophagy (1) Bacterial (2) Beta-secretase (10) CaMK (1) Cannabinoid Receptor (1) CDK (1) Cholinesterase (ChE) (22) EGFR (1) Ephrin Receptor (1) Fluorescent Dye (2) G-quadruplex (1) GABA Receptor (1) GSK-3 (2) iGluR (2) Keap1-Nrf2 (2) Lipoxygenase (1) mGluR (1) Monoamine Oxidase (3) mTOR (1) NF-κB (2) Potassium Channel (1) Prolyl Endopeptidase (PREP) (1) Reactive Oxygen Species (2) ROS Kinase (2) Sigma Receptor (2) Somatostatin Receptor (1) Steroid Sulfatase (1) Tau Protein (2) TMV (1) γ-secretase (8)
By Research Areas:	Cancer (3) Cardiovascular Disease (3) Endocrinology (1) Infection (1) Inflammation/Immunology (7) Metabolic Disease (1) Neurological Disease (101)
Click Chemistry:	Azide (1) Alkynes (1)

110

Inhibitors & Agonists

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Click Chemistry

Targets Recommended: Amyloid-β

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-149583

Aβ-IN-8	Amyloid-β	Neurological Disease
Aβ-IN-8 (compound 7e) is a potent inhibitor of the Aβ aggregation .

HY-149582

Aβ-IN-7	Amyloid-β	Neurological Disease
Aβ-IN-7 (compound 5a) is a potent inhibitor of the Aβ aggregation. Aβ-IN-7 with 50 μM stabilize Aβ monomers in the small oligomeric species and prolong the nucleation process. Aβ-IN-7 inhibits Aβ fibril formation better than Aβ-IN-8 (HY-149583) in 50 μM .

HY-150003

Aβ1–42 aggregation inhibitor 1	Cholinesterase (ChE) Amyloid-β	Neurological Disease
Aβ1-42 aggregation inhibitor 1 inhibits AChE (acetylcholinesterase) and BuChE (butyrylcholinesterase) with the IC₅₀ value of 2.64 μM and 1.29 μM, respectively. Aβ1-42 aggregation inhibitor 1 inhibits self-mediated Aβ1-42 aggregation by 51.29% at a concentration of 25 μM. Aβ1-42 aggregation inhibitor 1 has the potential for the research of anti-Alzheimer's disease .

HY-149246

Aβ-IN-6	Amyloid-β Keap1-Nrf2	Neurological Disease Inflammation/Immunology
Aβ-IN-6 reduces pro-inflammatory cytokine release from microglia cells. Aβ-IN-6 significantly induces Nrf2 nuclear translocation and hamperes Aβ oligomers formation. Aβ-IN-6 exerts a consistent neuroprotective effect by modulating the redox-sensitive signalling pathways in vivo oxidative stress model. Aβ-IN-6 is an orally active and has antiinflammatory, Antioxidant and Anti-oligomeric activity. Aβ-IN-6 has the potential for Alzheimer's disease (AD) research .

HY-144326

Aβ-IN-1	Amyloid-β	Neurological Disease
Aβ-IN-1 is a Aβ1–42 aggregation inhibitor. Aβ-IN-1 inhibits Aβ1-42 self-aggregation in vitro by delaying the exponential growth phase or reduces the quantity of fibrils in the steady state. Aβ-IN-1 can be used for the research of conformational disorders .

HY-144327

Aβ-IN-2	Amyloid-β	Neurological Disease
Aβ-IN-2 is a Aβ1–42 aggregation inhibitor. Aβ-IN-2 inhibits Aβ1-42 self-aggregation in vitro by delaying the exponential growth phase or reduces the quantity of fibrils in the steady state. Aβ-IN-2 can be used for the research of conformational disorders .

HY-146140

Aβ-IN-4	Amyloid-β	Neurological Disease
Aβ-IN-4 (compound 12) is a potent amyloid β (Aβ) inhibitor. Aβ-IN-4 inhibits Aβ42 aggregation. However, Aβ-IN-4 can not alleviate the neurotoxicity of Aβ42 in SH-SY5Y cells. Aβ-IN-4 can not change the aggregation state of Aβ42 into a nontoxic one .

HY-146139

Aβ-IN-3	Amyloid-β	Neurological Disease
Aβ-IN-3 (compound 1) is a potent amyloid β (Aβ) inhibitor. Aβ-IN-3 inhibits Aβ42 aggregation. However, Aβ-IN-3 can not alleviate the neurotoxicity of Aβ42 in SH-SY5Y cells. Aβ-IN-3 can not change the aggregation state of Aβ42 into a nontoxic one .

HY-147980

Aβ-IN-5	Amyloid-β Cholinesterase (ChE)	Neurological Disease
Aβ-IN-5 (Compound e12) is an orally active Aβ aggregation inhibitor. Aβ-IN-5 also inhibits AChE and BuChE with IC₅₀ values of 21.29 μM and 1.32 μM, respectively. Aβ-IN-5 shows excellent neuroprotective effects and low neurotoxicity .

HY-161658

Aβ-IN-9	Amyloid-β	Neurological Disease
Aβ-IN-9 (Compound 6i) is an amyloid-beta aggregation inhibitor. Aβ-IN-9 can inhibit Aβ aggregation to form nano-rod-like structures, thereby preventing β-sheet formation. Aβ-IN-9 can be used for Alzheimer's disease research .

HY-169268

Aβ-IN-10	Amyloid-β	Neurological Disease
Aβ-IN-10 (Compound Alz -5) is a bifunctional copper chelator and an inhibitor for beta-amyloid (Aβ), that interacts with Aβ aggregates and reduces the neurotoxicity. Aβ-IN-10 exhibits antioxidant efficacy, reveals moderate cytotoxicity with the presence of CuCl₂ in SH-SY5Y and HepG2 with IC₅₀ of 65.5, 31.2 μM. Aβ-IN-10 reduces the increase of cell stiffness caused by Aβ .

HY-P3688

β-Amyloid (1-38) Aβ (1-38); Aβ38	Amyloid-β	Others
β-Amyloid (1-38) (Aβ (1-38); Aβ38) is aAβ Fragment.

HY-136866

Aβ42-IN-2	γ-secretase	Neurological Disease
Aβ42-IN-2 is a γ-secretase modulator extracted from patent WO2016070107, compound example 36. Aβ42-IN-2 has an IC₅₀ of 6.5 nM for Αβ₄₂. Aβ42-IN-2 can be used for the research of Alzheimer's disease .

HY-130609

Aβ42-IN-1	γ-secretase	Neurological Disease
Aβ42-IN-1, compound 1v, is a novel, potent and orally active γ-secretase modulator (GSM). Aβ42-IN-1 potently reduced Aβ42 levels with an IC₅₀ value of 0.091 µM without CYP3A4 inhibition. Aβ42-IN-1 shows a sustained pharmacokinetic profile.

HY-149763

Aβ42 agonist-1	Amyloid-β	Neurological Disease
Aβ42 agonist-1 (compound 7a) is a small molecule compound that can promote Aβ42 aggregation. Aβ42 agonist-1 can interact with Aβ42 oligomers and pentamers to promote nontoxic aggregate self-assembly and rapid fibril formation. Aβ42 agonist-1 prevents Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells .

HY-149764

Aβ42 agonist-2	Amyloid-β	Neurological Disease
Aβ42 agonist-2 (compound 7b) is a small molecule compound that can promote Aβ42 aggregation. Aβ42 agonist-2 can interact with Aβ42 oligomers and pentamers to promote nontoxic aggregate self-assembly and rapid fibril formation. Aβ42 agonist-2 prevents Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells .

HY-161109

Aβ42-IN-4	Amyloid-β	Neurological Disease
Aβ42-IN-4 (compound 0043) degrades amyloid precursor protein (APP) and reduces Aβ42 production .

HY-161110

Aβ42-IN-5	Amyloid-β	Neurological Disease
Aβ42-IN-5 (Compound 0152) is an oral active amyloid precursor protein (APP) degrader that can reduce Aβ42 in Alzheimer's disease iPSC neurons. Aβ42-IN-5 can bind CAPRIN1 and APP and enhance the protein-protein interaction .

HY-13325

Aβ42-IN-6	Others	Others
Aβ42-IN-6 is an active compound.

HY-141661

Aβ/tau aggregation-IN-1	Amyloid-β	Neurological Disease
Aβ/tau aggregation-IN-1 is a potent Aβ_1-42 β-sheets formation and tau aggregation inhibitor. The K_D values of Aβ/tau aggregation-IN-1 with Aβ_1-42 and tau are 160 μM and 337 μM, respectively. Aβ/tau aggregation-IN-1 can permeate the blood-brain barrier .

HY-153430

Aβ/tau aggregation-IN-3	Amyloid-β	Neurological Disease
Aβ/tau aggregation-IN-3 is a potent amyloid protein aggregation inhibitor with an IC₅₀ of 0.85 μM by Aβ-Thioflavin T (Aβ-ThT) functional aggregation assay. Aβ/tau aggregation-IN-3 has anti-amyloid activity .

HY-130609A

Aβ42-IN-1 free base	γ-secretase	Neurological Disease
Aβ42-IN-1 free base (compound 1v) is an orally active, high brain exposure γ-secretase modulator. Aβ42-IN-1 free base potently reduces Aβ42 levels with an IC₅₀ value of 0.091 µM, and significantly reduces brain Aβ42 levels in mice. Aβ42-IN-1 free base is a promising compound for the treatment of Alzheimer’s disease .

HY-139740

Aβ Fibrillization modulator 1	Amyloid-β	Neurological Disease
Aβ Fibrillization modulator 1 stabilizes Aβ monomers.

HY-P3779

Amyloid 17-42 Aβ(17-42)	Apoptosis	Neurological Disease
Amyloid 17-42 (Aβ(17-42)) is a major constituent of diffuse plaques in Alzheimer's disease and cerebellar pre-amyloid in Down's syndrome, derived by alpha- and gamma-secretase cleavage of the amyloid precursor protein (APP). Amyloid 17-42 can induce neuronal apoptosis via a Fas-like/caspase-8 activation pathway .

HY-P3275

β-Amyloid (17-40) Aβ(17-40)	Amyloid-β	Neurological Disease
β-Amyloid (17-40) (Aβ(17-40)) is a fragment of Amyloid-β peptide that has shown neurotoxic activities in SH-SY5Y and IMR-32 cells. β-Amyloid (17-40) can be used for the research of neurological disease .

HY-162093

Aβ1–42 aggregation inhibitor 2	Amyloid-β	Neurological Disease
Aβ1–42 aggregation inhibitor 2 (compound 7c) is a potent inhibitor of Aβ1-42 aggregation that plays an important role in Alzheimer's disease research. Aβ1–42 aggregation inhibitor 2 displays excellent antioxidant, metal ions chelating, oxidative stress alleviation, neuroprotective and anti-neuroinflammatory activities .

HY-P5333A

Aβ1-14-εK-KKK-MvF5 Th acetate UB311 immunogen I acetate	Amyloid-β	Neurological Disease
Aβ1-14-εK-KKK-MvF5 Th acetate is the acetate salt form of Aβ1-14-εK-KKK-MvF5 Th (HY-P5333). Aβ1-14-εK-KKK-MvF5 Th acetate is part of UB-311 vaccine, that targets the amyloid-beta (Aβ) protein, and ameliorates the Alzheimer’s disease .

HY-P0128

β-Amyloid (25-35) Maximum Cited Publications 28 Publications Verification Amyloid beta-peptide (25-35); Aβ25-35; β-Amyloid peptide (25-35)	Amyloid-β	Neurological Disease
β-Amyloid (25-35) (Amyloid beta-peptide (25-35)) is the fragment Aβ(25-35) of the Alzheimer's amyloid β-peptide, has shown neurotoxic activities in cultured cells .

HY-157440

AChE/Aβ-IN-3	Amyloid-β Reactive Oxygen Species Cholinesterase (ChE)	Neurological Disease
AChE/Aβ-IN-3 (compound AM5) is a dual inhibitor of AChE and Amyloid-β aggregation with IC_50<.sub> values of 1.29 and 4.93 μM, respectively. AChE/Aβ-IN-3 has antioxidant properties that scavenge ROS and restore their normal levels. AChE/Aβ-IN-3 can be used in the study of neurological diseases, such as Alzheimer's disease .

HY-155733

AChE/Aβ-IN-1	iGluR Cholinesterase (ChE) Amyloid-β	Neurological Disease
AChE/Aβ-IN-1 (compound 32) is a potent and orally active inhibitor of acetylcholinesterase (AChE) with an IC₅₀ of 86 nM, as well as an antagonist of NMDA receptor (GluN1-1b/GluN2B subunit combination) with IC₅₀ of 3.876 μM. AChE/Aβ-IN-1 also inhibits Aβ aggregation and shows good blood-brain barrier permeability and neuroprotection. AChE/Aβ-IN-1 improves cognitive and spatial memory impairment in rats model .

HY-155735

AChE/Aβ-IN-2	iGluR Cholinesterase (ChE) Amyloid-β	Neurological Disease
AChE/Aβ-IN-2 (compound 33) is a potent and orally active inhibitor of acetylcholinesterase (AChE) with IC₅₀ of 135 nM, as well as an antagonist of NMDA receptor (GluN1-1b/GluN2B subunit combination) with IC₅₀ of 5.054 μM. AChE/Aβ-IN-2 also inhibits Aβ aggregation and shows good blood-brain barrier permeability. AChE/Aβ-IN-2 improves cognitive and spatial memory impairment in rats model .

HY-157441

AChE/Aβ-IN-4	Cholinesterase (ChE) Amyloid-β	Neurological Disease
AChE/Aβ-IN-4 is a dual inhibitor of acetylcholinesterase (AChE) and β-amyloid (Aβ) aggregation, with the IC₅₀ values of 1.72 ± 0.18 μM and 1.42 ± 0.3 μM, respectively. AChE/Aβ-IN-4 plays an impotant role in neurological disorders, such as Alzheimer’s disease .

HY-163320

AChE/Aβ-IN-5	Cholinesterase (ChE) Amyloid-β	Neurological Disease
AChE/Aβ-IN-5 (compound AV-2) is a bifunctional inhibitor that targets AChE and auto-induced Aβ (Amyloid-β) aggregation. AChE/Aβ-IN-5 can significantly improve scopolamine- and Aβ-induced cognitive impairment in mice .

HY-159151

AChE/Aβ-IN-6	Beta-secretase Amyloid-β	Neurological Disease
BACE1-IN-15 (compound 4j) is a potent inhibitor of BACE1 (β-secretase) that can inhibited the copper ion induced Aβ toxicity, with the EC₅₀ of 0.68 μM .

HY-146483

Anti-Aβ agent 1A	Amyloid-β	Neurological Disease Inflammation/Immunology
Anti-Aβ agent 1A (compound M15) has potent activity against amyloid-β. Anti-Aβ agent 1A possesses can significantly inhibit LPS-induced levels of IL-1β, IL-6 and TNF-α, and reduces the apoptosis of SH-SY5Y induced by H₂O₂ through mitochondria pathway. Anti-Aβ agent 1A possesses antioxidant, anti-inflammatory, anti-Aβ toxicity and neuroprotective activities. Anti-Aβ agent 1A can be used for researching Alzheimer’s disease (AD) .

HY-P5905

Citrullinated amyloid-β (1-42) peptide (human) Citrullinated Aβ (1-42); Citrullinated Aβ42	Amyloid-β	Neurological Disease
Citrullinated amyloid-β (1-42) peptide (human) (Citrullinated Aβ (1-42)) is a modified form of β-Amyloid (1-42) (HY-P1363) with a citrullination at the Arg5 site. Compared to the unmodified β-Amyloid (1-42), its formation of soluble low-molecular-weight oligomers is enhanced, the rate of fibril formation is reduced, and like unmodified Aβ42, it forms protofibrils comprised of parallel β-sheets .

HY-P5906

Citrullinated amyloid-β (1-40) peptide (human) Citrullinated Aβ (1-40); Citrullinated Aβ40	Amyloid-β	Neurological Disease
Citrullinated amyloid-β (1-40) peptide (human) (Citrullinated Aβ (1-40)) is a modified form of β-Amyloid (1-40) (HY-P0265) with a citrullination at the Arg5 site. Citrullinated amyloid-β (1-40) peptide (human) exhibits increased transient formation of soluble oligomers and insoluble aggregates composed of distorted parallel β-sheets compared with unmodified β-Amyloid (1-40) .

HY-144388

ChE/Aβ1-42-IN-1	Cholinesterase (ChE) Amyloid-β	Neurological Disease
ChE/Aβ1-42-IN-1 (compound 28) is a potent ChE and Aβ_1-42 aggregation inhibitor with IC₅₀s of 0.062, 0.767 and 1.227 µM for AChE, BuChE and Aβ_1-42 aggregation, respectively. ChE/β1-42-IN-1 shows excellent BBB penetration. ChE/Aβ1-42-IN-1 is a potent multi-targeted anti-Alzheimer's agent .

HY-144389

hAChE/Aβ1-42-IN-1	Cholinesterase (ChE) Amyloid-β	Neurological Disease
hAChE/Aβ1-42-IN-1 (Compound 16) is a potent inhibitor of hAChE and Aβ1-42 aggregation. hAChE/Aβ1-42-IN-1 shows acceptable relative safety upon hepG2 cell line and excellent BBB penetration with wide safety margin. hAChE/Aβ1-42-IN-1 has the potential for the research of Alzheimer disease (AD) .

HY-149272

tau/Aβ40 aggregation-IN-1	Tau Protein Amyloid-β Cholinesterase (ChE)	Neurological Disease
tau/Aβ40 aggregation-IN-1 (Compound 20) is a tau and Aβ₄₀ aggregation inhibitor with IC₅₀s of 1.8 μM and 1.3 μM, respectively .

HY-P99216

Ponezumab 1 Publications Verification PF-04360365; RN 1219	EGFR	Neurological Disease
Ponezumab (PF-04360365) is a humanised anti-amyloid IgG2 monoclonal antibody. Ponezumab reduces Aβ levels in the central nervous system and improves performance in mice in various models of learning and memory. Ponezumab can be used in study of Alzheimer's disease .

HY-107758

Y-29794 oxalate	Prolyl Endopeptidase (PREP)	Cancer
Y-29794 oxalate is a selective, orally active and blood-brain barrier permeable non-peptide prolyl endopeptidase inhibitor. Y-29794 oxalate blocks the IRS1-AKT-mTORC1 pathway and inhibits tumor growth. Y-29794 oxalate is also effective in inhibiting the progression of Aβ-like deposition in the hippocampus of aging-accelerated mice (SAM) .

HY-P10578

SEN 304	Amyloid-β	Neurological Disease
SEN 304 is an Aβ aggregation inhibitor. SEN 304 can bind directly to Aβ(1-42), delay β-sheet formation and promote aggregation of toxic oligomers into a nontoxic form. SEN 304 can be used for research of Alzheimer’s disease .

HY-101514

β3-AR agonist 1	Adrenergic Receptor	Cardiovascular Disease Endocrinology
β3-AR agonist 1 (compound 15) is a highly potent, selective, and orally available β3-adrenergic receptor (β3-AR) agonist (EC₅₀=18 nM), being inactive to β1-, β2-, and α1A-AR (β1/β3, β2/β3, and α1A/β3>556-fold) .

HY-B0949

Protriptyline hydrochloride 3 Publications Verification	Cholinesterase (ChE)	Neurological Disease
Protriptyline hydrochloride is a tricyclic antidepressant (TCA), specifically a secondary amine, for the treatment of depression and ADHD.

HY-P2264

KYL peptide	Ephrin Receptor	Inflammation/Immunology
KYL peptide, an antagonistic peptide, selectively targets EphA4 receptor (IC₅₀:4.22 μM, Kd:1.3 μM). KYL peptide binds to the ligand-binding domain of EphA4, effectively alleviates Aβ-induced synaptic dysfunction and synaptic plasticity defects in AD mice. KYL peptide can promote nerve regeneration after injury and modulating immune responses .

HY-103538

JLK-6	Amyloid-β	Neurological Disease
JLK-6 markedly reduce the production of amyloid β-peptide (Aβ) by amyloid-β Precursor protein (APP) expressing HEK293 cells by affecting the γ-secretase cleavage of APP, with no effect on the cleavage of the Notch receptor .

HY-B0949A

Protriptyline	Cholinesterase (ChE) Amyloid-β	Neurological Disease
Protriptyline is a potent antidepressant agent. Protriptyline inhibits AChE activity with IC₅₀ value of 0.06 mM and inhibits Aβ Self-Assembly. Protriptyline can be used for depression and Alzheimers disease .

HY-148913

CS587	CaMK	Neurological Disease
CS587 is a specific inhibitor of CaMK1D with neurocytotoxicity at 10 μM. CS587 modulates the sensitivity of neuronal cells to Aβ oligomer toxicity .

HY-156011

PSEN1-IN-1	γ-secretase	Neurological Disease
PSEN1-IN-1 (Compound (+)-13b) is a PSEN1 inhibitor. PSEN1-IN-1 inhibits PSEN1-APH1A and PSEN1-APH1B complex with IC₅₀s of 19 and 5.5 nM. PSEN1-IN-1 can be used for Alzheimer's disease research .

Cat. No.	Product Name	Type

HY-133821

N-Methylmesoporphyrin IX

Fluorescent Dyes/Probes

N-Methylmesoporphyrin IX (NMM), a widely used G-quadruplex DNA specific fluorescent binder, is an efficient probe for monitoring Aβ fibrillation. N-Methylmesoporphyrin IX is an in situ inhibitor and an ex situ monitor for Aβ amyloidogenesis both in vitro and in cells. N-Methylmesoporphyrin IX is sensitive to G-quadruplexes DNA but has no response to duplexes, triplexes and single-stranded forms DNA. N-Methylmesoporphyrin IX is nonfluorescent alone or in monomeric Aβ environments, but emits strong fluorescence through stacking with the Aβ assemblies .

HY-111263

NIAD-4	Fluorescent Dyes/Probes
NIAD-4 is a fluorophore for optical imaging of amyloid-β (Aβ) in the central nervous system (CNS) for Alzheimer’s disease (AD). NIAD-4 binds to the same Aβ site with the binding affinity (K_i) of 10 nM .

HY-D0939

Direct Blue 1 Chicago Sky Blue 6B	Dyes
Direct Blue 1 (Chicago Sky Blue 6B) is a complex dye for background autofluorescence in immunofluorescence histochemistry. Direct Blue 1 is a potent and competitive VGLUT inhibitor. Direct Blue 1 can inhibit the Aβ-binding small molecule PrP ligand. Direct Blue 1 has anti-inflammatory activity .

HY-D2268

QM-FN-SO3	Fluorescent Dyes/Probes
QM-FN-SO₃ is a BBB-penetrable near-infrared (NIR) aggregation-induced emission (AIE)-active probe for Aβ plaques. QM-FN-SO₃ can be used for in vivo detection of Aβ plaques. QM-FN-SO₃ has ultra-high S/N ratio, binding affinity, and high-performance NIR emission .

HY-D2268A

QM-FN-SO3 ammonium	Fluorescent Dyes/Probes
QM-FN-SO₃ ammonium is a BBB-penetrable near-infrared (NIR) aggregation-induced emission (AIE)-active probe for Aβ plaques. QM-FN-SO₃ ammonium can be used for in vivo detection of Aβ plaques. QM-FN-SO₃ ammonium has ultra-high S/N ratio, binding affinity, and high-performance NIR emission .

Cat. No.	Product Name	Target	Research Area

HY-P5332

Aβ1-14-εK-HBsAg3 Th UB311 immunogen II	Peptides	Others
Aβ1-14-εK-HBsAg3 Th (UB311 immunogen II) is a biological active peptide. (one of UB-311's Aβ1–14–targeting peptides (B-cell epitope))

HY-P5333

Aβ1-14-εK-KKK-MvF5 Th UB311 immunogen I	Peptides	Others
Aβ1-14-εK-KKK-MvF5 Th (UB311 immunogen I) is a biological active peptide. (one of UB-311's Aβ1–14–targeting peptides (B-cell epitope))

HY-P5333A

Aβ1-14-εK-KKK-MvF5 Th acetate UB311 immunogen I acetate	Amyloid-β	Neurological Disease
Aβ1-14-εK-KKK-MvF5 Th acetate is the acetate salt form of Aβ1-14-εK-KKK-MvF5 Th (HY-P5333). Aβ1-14-εK-KKK-MvF5 Th acetate is part of UB-311 vaccine, that targets the amyloid-beta (Aβ) protein, and ameliorates the Alzheimer’s disease .

HY-P0128

β-Amyloid (25-35) 25+ Cited Publications Amyloid beta-peptide (25-35); Aβ25-35; β-Amyloid peptide (25-35)	Amyloid-β	Neurological Disease
β-Amyloid (25-35) (Amyloid beta-peptide (25-35)) is the fragment Aβ(25-35) of the Alzheimer's amyloid β-peptide, has shown neurotoxic activities in cultured cells .

HY-P5905

Citrullinated amyloid-β (1-42) peptide (human) Citrullinated Aβ (1-42); Citrullinated Aβ42	Amyloid-β	Neurological Disease
Citrullinated amyloid-β (1-42) peptide (human) (Citrullinated Aβ (1-42)) is a modified form of β-Amyloid (1-42) (HY-P1363) with a citrullination at the Arg5 site. Compared to the unmodified β-Amyloid (1-42), its formation of soluble low-molecular-weight oligomers is enhanced, the rate of fibril formation is reduced, and like unmodified Aβ42, it forms protofibrils comprised of parallel β-sheets .

HY-P3688

β-Amyloid (1-38) Aβ (1-38); Aβ38	Amyloid-β	Others
β-Amyloid (1-38) (Aβ (1-38); Aβ38) is aAβ Fragment.

HY-P3779

Amyloid 17-42 Aβ(17-42)	Apoptosis	Neurological Disease
Amyloid 17-42 (Aβ(17-42)) is a major constituent of diffuse plaques in Alzheimer's disease and cerebellar pre-amyloid in Down's syndrome, derived by alpha- and gamma-secretase cleavage of the amyloid precursor protein (APP). Amyloid 17-42 can induce neuronal apoptosis via a Fas-like/caspase-8 activation pathway .

HY-P3275

β-Amyloid (17-40) Aβ(17-40)	Amyloid-β	Neurological Disease
β-Amyloid (17-40) (Aβ(17-40)) is a fragment of Amyloid-β peptide that has shown neurotoxic activities in SH-SY5Y and IMR-32 cells. β-Amyloid (17-40) can be used for the research of neurological disease .

HY-P5906

Citrullinated amyloid-β (1-40) peptide (human) Citrullinated Aβ (1-40); Citrullinated Aβ40	Amyloid-β	Neurological Disease
Citrullinated amyloid-β (1-40) peptide (human) (Citrullinated Aβ (1-40)) is a modified form of β-Amyloid (1-40) (HY-P0265) with a citrullination at the Arg5 site. Citrullinated amyloid-β (1-40) peptide (human) exhibits increased transient formation of soluble oligomers and insoluble aggregates composed of distorted parallel β-sheets compared with unmodified β-Amyloid (1-40) .

HY-P10040

(Gln22)β-Amyloid (1-40) human	Peptides	Neurological Disease
(Gln22)β-Amyloid (1-40) human is an amyloid beta protein (Aβ)-containing peptide used in Alzheimer's disease research .

HY-P10578

SEN 304	Amyloid-β	Neurological Disease
SEN 304 is an Aβ aggregation inhibitor. SEN 304 can bind directly to Aβ(1-42), delay β-sheet formation and promote aggregation of toxic oligomers into a nontoxic form. SEN 304 can be used for research of Alzheimer’s disease .

HY-P2264

KYL peptide	Ephrin Receptor	Inflammation/Immunology
KYL peptide, an antagonistic peptide, selectively targets EphA4 receptor (IC₅₀:4.22 μM, Kd:1.3 μM). KYL peptide binds to the ligand-binding domain of EphA4, effectively alleviates Aβ-induced synaptic dysfunction and synaptic plasticity defects in AD mice. KYL peptide can promote nerve regeneration after injury and modulating immune responses .

HY-P3845

(Gly22)-Amyloid β-Protein (1-42)	Amyloid-β	Neurological Disease
(Gly22)-Amyloid β-Protein (1-42) is a peptide fragment of amyloid β-protein (Aβ). Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease. Mutation of Glu22 to Gly22 in Aβ can increase aggregation .

HY-P3846

(Glu20)-Amyloid β-Protein (1-42)	Amyloid-β	Neurological Disease
(Glu20)-Amyloid β-Protein (1-42) is a slower fibrillizing variant of amyloid β-protein (Aβ). The Glu20 mutation reduces the aggregation propensity of Aβ42 and prevents accumulation of the slowly fibrillizing peptide. Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease .

HY-P5156

BDS-I	Potassium Channel	Neurological Disease
BDS-I known as blood depressing substance, is a marine toxin which can be extracted from Anemonia sulcata. BDS-I is a specific inhibitor of Potassium Channel, targeting to Kv3.4. BDS-I inhibits Aβ1-42-induced enhancement of KV3.4 activity, caspase-3 activation, and abnormal nuclear morphology of NGF-differentiated PC-12 cells. BDS-I reverts the Aβ peptide-induced cell death .

HY-P1206

CH 275	Somatostatin Receptor	Neurological Disease
CH 275 is a peptide analog of somatostatin and binds preferably to somatostatin receptor 1 (sst₁) with a K_i of 52 nM . CH 275 acts as a potent and selective sst₁ agonist (IC₅₀=30.9 nM) and also displays IC₅₀ values of 345 nM, >1 μM, >10 μM, >10 μM for human sst₃, sst₄, sst₂ and sst₅, respectively . CH 275 can be used for the research of alzheimer’s disease .

HY-W111226

Fmoc-His(3-Me)-OH	Amyloid-β Amino Acid Derivatives	Cardiovascular Disease
Fmoc-His(3-Me)OH derives Histidine-associating compounds with biological activity. Fmoc-His(3-Me)OH, with Fmoc-citrulline-OH, Fmoc-His(1-Me)-OH together, forms tri-peptides and shows vasodilating effect with EC₅₀s of 2.7-4.7 mM in 1.0 mM Phenylephrine (PE)-contracted aorta rings. Fmoc-His(3-Me)OH (resin) also makes Methyl-His-Gly-Lys (His(3-Me)-Gly-Lys), thus acts as an [Ca ²⁺]_i inhibitor. Fmoc-His(3-Me)OH methylates NAHIS02, making it unable to block the Alzheimer's Aβ channel .

Cat. No.	Product Name	Target	Research Area

HY-P99216

Ponezumab 1 Publications Verification PF-04360365; RN 1219	EGFR	Neurological Disease
Ponezumab (PF-04360365) is a humanised anti-amyloid IgG2 monoclonal antibody. Ponezumab reduces Aβ levels in the central nervous system and improves performance in mice in various models of learning and memory. Ponezumab can be used in study of Alzheimer's disease .

HY-P99859

Donanemab LY3002813	Amyloid-β	Neurological Disease
Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N-terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research .

HY-P9999

Trontinemab RG6102; RO-7126209	Amyloid-β	Neurological Disease
Trontinemab (RG6102) is a brain-penetrant, anti-amyloid, bispecific and humanizedized IgG1-κ antibody, targeting to Aβ plaques and transferrin receptor 1 (TFR1). Trontinemab binds to fibrillar Aβ as well as Aβ plaques triggering plaque clearance by engaging immune cells on Alzheimer disease (AD) brain sections. Trontinemab also shows specific affinity to cynomolgus and human TFR1 .

HY-P990078

Remternetug LY3372993	Amyloid-β	Neurological Disease
Remternetug is a human immunoglobulin G1-kappa, anti-APP (amyloid beta A4 precursor protein) Aβ42 N3pGlu peptide monoclonal antibody. Remternetug recognizes a pyroglutamated form of Aβ that aggregates into amyloid plaques .

Cat. No.	Product Name		Classification

HY-16361A

Omigapil maleate CGP3466B; CGP3446 maleate; TCH346 maleate		Alkynes
Omigapil maleate, an orally bioavailable GAPDH nitrosylation inhibitor, abrogates Aβ_1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice. Omigapil maleate has the potential for the research of Alzheimer's disease . Omigapil maleate (CGP3446B maleate) is a apoptosis inhibitor. Omigapil maleate can be used for the research of congenital muscular dystrophy (CMD) . Omigapil (maleate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-159151

AChE/Aβ-IN-6		Azide
BACE1-IN-15 (compound 4j) is a potent inhibitor of BACE1 (β-secretase) that can inhibited the copper ion induced Aβ toxicity, with the EC₅₀ of 0.68 μM .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks